WORK Medical Technology Group LTD Class A Ordinary Shares
2.37
USD
Patrocinado
+0.44
+22.54%
08 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
2.25
-0.11
-4.65%
Relatórios de Lucros WOK
Rácio de surpresa positiva
Nenhum Dado Disponível para WOK
%
Próximo Relatório
Data do Próximo Relatório
03 de fev. de 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
--
Mudanças implicadas deQ-- --(Revenue/ EPS)
--
/
--
Mudanças implicadas deQ4 24(Revenue/ EPS)
--
/
--
WORK Medical Technology Group LTD Class A Ordinary Shares earnings per share and revenue
On --, WOK reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, -- analistas forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
What were WORK Medical Technology Group LTD Class A Ordinary Shares's earnings and revenue for the latest quarter Q-- --?
For Q-- --, WORK Medical Technology Group LTD Class A Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to WORK Medical Technology Group LTD Class A Ordinary Shares's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is WORK Medical Technology Group LTD Class A Ordinary Shares expected to report next?
The next earning report is scheduled for 03 de fev. de 2026.
What are the forecasts for WORK Medical Technology Group LTD Class A Ordinary Shares's next earnings report?
Based on --
analistas, WORK Medical Technology Group LTD Class A Ordinary Shares is expected to report EPS of -- and revenue of -- for Q4 2025.